All the news Showing 10 of 848 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Antiviral therapy 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Epidemiology Few countries will meet 2020 target for reducing viral hepatitis deaths Keith Alcorn / 24 November 2020 Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ... Antiviral therapy Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... Finance, funding & health economics Can investment in hepatitis C treatment be cost saving? Keith Alcorn / 24 November 2020 Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ... Mother to child Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission Liz Highleyman / 20 November 2020 Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to their infants, according to a pair of studies presented ... Monitoring response to treatment Minimal monitoring of hepatitis C treatment is safe and effective Keith Alcorn / 17 November 2020 Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ... New and experimental treatments for hepatitis B NASVAC therapeutic vaccine may lead to functional cure of hepatitis B Liz Highleyman / 17 November 2020 NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ... Coronavirus Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... Coronavirus Which people with chronic liver disease have higher COVID-19 risks? Keith Alcorn / 16 November 2020 Decompensated cirrhosis, alcoholic liver disease and hepatocellular carcinoma each raise the risk of death and severe illness from COVID-19 among people with chronic liver disease, but other liver conditions do not, a US ... Treatment for people who use drugs Peers of drug users play key roles in hepatitis C treatment decision-making Keith Alcorn / 04 November 2020 Peers are important sources of information about hepatitis C treatment and may be the most persuasive advocates for engaging with treatment and care among drug users, a study in Melbourne, Australia, shows. People ... ← Prev12345...85Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds